GE Healthcare, Eli Lilly, ABI, Olink Bioscience, Perlegen, 454, Invitrogen, Natural Selection, Bio-Rad, DiaMed, Celera, Siemens, Salk Institute, Univ. of Marburg, Abbott, Epigenomics, SeqWright | GenomeWeb
GE Healthcare, Lilly to Develop IVDs for Cancer Therapy Prediction
 
Eli Lilly has signed a three-year collaboration with GE Healthcare and GE Global Research to develop in vitro diagnostics to predict the response of patients to targeted cancer therapies, the companies said this week.
 
The collaboration covers targeted cancer therapeutics under development at Lilly and GE’s multiplexed tissue-based assays and image analysis tools.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.